This inventor holds 1 USPTO granted patent. Top assignee: Oncodesign Sa. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: The Innovations of Pascal André René Benderitter
Introduction
Pascal André René Benderitter is a notable inventor based in St Apollinaire, France. He has made significant contributions to the field of biotechnology, particularly in the development of kinase inhibitors. His work focuses on creating innovative solutions for medical applications.
Latest Patents
Benderitter holds a patent for "Macrocyclic RIP2-kinase inhibitors." This invention relates to macrocyclic compounds and compositions that act as kinase inhibitors, specifically targeting RIP2-kinase and its mutants. The patent outlines methods for using these compounds in the diagnosis, prevention, and treatment of diseases associated with RIP2-kinase. The invention includes a compound according to Formula(I) and its various forms, such as stereoisomers, tautomers, and salts.
Career Highlights
Benderitter is associated with Oncodesign SA, a company that specializes in drug discovery and development. His work at Oncodesign has allowed him to contribute to advancements in cancer treatment and other therapeutic areas. His innovative approach has positioned him as a key figure in the biotechnology sector.
Collaborations
Benderitter has collaborated with notable colleagues, including Yann Lamotte and Nérina Dodic. These partnerships have fostered a collaborative environment that enhances research and development efforts within the company.
Conclusion
Pascal André René Benderitter's contributions to the field of biotechnology through his patent on RIP2-kinase inhibitors exemplify his innovative spirit and dedication to improving medical treatments. His work continues to impact the industry positively.